You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, join our community today!
The banners on the left side and below do not show for registered users!
If you have any problems with the registration process or your account login, please contact contact us.
The Business and Financial ForumTHIS SPACE OPEN FOR ADVERTISEMENT. YOU SHOULD BE ADVERTISING HERE! Revscene Wall Street.
Consolidating debt? Good business tips? Buying stock? How's our economy doing? Discuss and share advice and tools on everyday banking, investing, wealth management and insurance.
TBH, I don't think you can really do much at all with just $100... unless you start off playing with options which is a bit more difficult than just buying/selling stocks. With $100 your really limited to just playing with stocks < 20$... and even then, growth potential is very minimal.
Go onto google finance and search up some companies you would like to buy.. Apple costs around 600$/share, CIBC costs around 70$/share... the lower cap / cheaper stocks that people on this forum are currently talking about include AMRN (~15$), BAC (~8$), YNG (~0.40), CLL (~0.30) etc.
so its my first time looking into this. what are my options that i can do with 100$? some site that i found on google said that i can start off with that price at minimum.
which sites do you guys look at to check for your stocks? what are the things that i should be looking out for?
.... 100$ for capital markets are you serious right now? Go to the casino, 100$ on red much better option for you You need G's bro unless your some fucking option wizard but options commission is $$$$ so.. you figure it out.
Hey guys I'm new to the stock market. Been reading a lot and I'm on the verge of buying some stocks. I have 5k I want to invest in blue chip companies in the s&p/tsx. I've been checking some stocks on my Bloomberg mobile and observing the price movement. What important aspects of a stock sould I look for before purchasing? What do you guys evaluate before purchasing? Any tips would be great. My plan is to diversify 1k~ to 4-5 companies
My AFC gave me an ABS CEL code of LOL while at WOT!
Join Date: Sep 2011
Location: RevScene.net
Posts: 1,889
Thanked 1,284 Times in 420 Posts
^ Not sure which company's you're planning to invest in, but you did mention you have 5k.
Diversifying 1k into 4-5 companies might be a bit...too tight. Maybe have a budget of at least 3-4k?
Anybody own nexen? Ive been a shareholder for like 2 years in my rsp, glad it finally paid off, although my average is like $20 a share though, so still super happy
^ remember, just because you like the brand doesnt mean it's a good investment
Yes I do realize that and I'm asking what are things that you guys look for in a company before purchasing. How do you determine the better company(s) in each sector?
Anybody own nexen? Ive been a shareholder for like 2 years in my rsp, glad it finally paid off, although my average is like $20 a share though, so still super happy
Yes I do realize that and I'm asking what are things that you guys look for in a company before purchasing. How do you determine the better company(s) in each sector?
I looks at PE ratio, profit margin, potential growth
I just took a quick look on google finance but it looks like Bauer and Sony had negative quarters and they have a low profit margin...
I personally have western energy..hopefully earnings on Aug 8 will give SP some strength...
Yes I do realize that and I'm asking what are things that you guys look for in a company before purchasing. How do you determine the better company(s) in each sector?
In addition to the answers above I look at the management team.
Yes I do realize that and I'm asking what are things that you guys look for in a company before purchasing. How do you determine the better company(s) in each sector?
If I were you, I would only look at the best companies in each sector.
Don't forget qualitative factors like competitive advantages, threats, strategy, etc..
Oh and technical analysis - don't go too crazy here, just draw a trend line.
24, 2012Amarin Announces Publication of ANCHOR Phase 3 Clinical Trial Results in The American Journal of Cardiology
BEDMINSTER, N.J., and DUBLIN, Ireland, July 24, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the results of its pivotal ANCHOR Phase 3 clinical trial are now available electronically through The American Journal of Cardiology and are scheduled for print publication in the October 2012 issue.
The publication, titled "Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR study)," describes the previously reported results of the Phase 3 ANCHOR clinical trial of Amarin's product candidate AMR101, in which all primary and secondary endpoints were achieved.
The ANCHOR trial, a multicenter, placebo-controlled, randomized, double-blind, 12-week study, investigated AMR101 as a treatment for high triglycerides (≥200 and < 500mg/dL) in 702 patients with mixed dyslipidemia (two or more lipid disorders) on background statin therapy at LDL-C (low-density lipoprotein cholesterol) goal who were at high risk of cardiovascular disease. The trial was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The trial's primary endpoint was defined as the percentage change in triglyceride levels from baseline compared to placebo after twelve weeks of treatment.
"The ANCHOR trial results exemplify why AMR101 has the potential to become an important lipid-lowering therapy. Not only did AMR101 demonstrate statistically significant decreases in triglyceride levels, but it did so with a statistically significant decrease in LDL-C beyond the decrease from optimized statin therapy at the 4 gram dose and showed non-inferiority at the 2 gram dose," stated Christie M. Ballantyne, M.D., Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas, and principal investigator of the ANCHOR trial. "In addition to reductions in triglycerides and LDL-C reductions, AMR101 also demonstrated statistically significant reductions in non-HDL-C, Apo-B, Lp-PLA2 and VLDL-C, all important lipid biomarkers. The favorable ANCHOR trial results provide a strong rationale for conducting Amarin's REDUCE-IT trial, the cardiovascular outcomes study of AMR101, which is currently recruiting patients at high risk for cardiovascular events."
About AMR101
AMR101 (icosapent ethyl) is a patented, ultra pure omega-3 fatty acid, comprising not less than 96% EPA (icosapent ethyl), that Amarin is developing as a treatment for patients with very high triglyceride levels (≥500 mg/dL), and for patients with high triglyceride levels (≥200 and < 500mg/dL) who are also on statin therapy for elevated low-density lipoprotein cholesterol, or LDL-C, levels (which we refer to as mixed dyslipidemia). The efficacy and safety of AMR101, an investigational drug, were studied in two Phase 3 clinical trials, the MARINE trial, which studied patients with very high triglyceride levels, and the ANCHOR trial, which studied patients with high triglyceride levels who were also on statin therapy for elevated LDL-C levels. These two Phase 3 clinical trials showed favorable results in triglyceride reduction compared to placebo in the studied patient populations. Reduction in triglyceride levels was achieved without a statistically significant increase in LDL-C levels, and in the 4 gram AMR101 ANCHOR results, with a statistically significant decrease in LDL-C levels. These trials also showed favorable results, particularly with the 4 gram dose of AMR101, in other important lipid and inflammation biomarkers, including Apo-B, non-HDL-C, Total-Cholesterol, VLDL-C, Lp-PLA2, and hs-CRP. In these trials, AMR101 exhibited a safety profile comparable to placebo. In December 2011, Amarin commenced patient dosing in a cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with EPA — Intervention Trial), that is designed to evaluate the efficacy of AMR101 in reducing major cardiovascular events in a high risk patient population on statin therapy.
About Amarin
Amarin Corporation plc is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. Amarin has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate, AMR101, in the treatment of patients with very high triglyceride levels (the population studied in Amarin's MARINE trial), and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 26, 2012. Amarin plans to separately seek approval for use of AMR101 in the treatment of patients with high triglyceride levels who are also on statin therapy for elevated LDL-C levels, the population studied in the ANCHOR trial, if the FDA approves the MARINE indication and after the REDUCE-IT cardiovascular outcomes trial is substantially underway. Each of the MARINE, ANCHOR and REDUCE-IT studies is the subject of a Special Protocol Assessment (SPA) agreement with the FDA.
Forward-looking statements
This press release contains forward-looking statements, including statements about the efficacy, safety and therapeutic benefits of Amarin's product candidates, clinical trial results, timing of publication, including statements about the clinical importance of certain biomarkers and the impact of AMR101 on such biomarkers. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that SPAs are not a guarantee that FDA will approve a product candidate upon submission; the risk that FDA may not complete its review of the NDA by the PDUFA goal date or grant new chemical entity regulatory exclusivity to AMR101; the risk that historical clinical trial enrollment and randomization rates may not be predictive of future results and related cost may increase beyond expectations; and the risk that publications of scientific data may not accept proposals to publish AMR101 data. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Amarin's product candidates are in various stages of development and are not available for sale or use outside of approved clinical trials. Nothing in this press release should be construed as promoting the use of such product candidates.
Care to tell us what it all means? I'm too busy at work to read this right now.
__________________
Quote:
Originally Posted by jasonturbo
Follow me on Instagram @jasonturtle if you want to feel better about your life
Just did some reading last night about pharm stocks so I'll take a newbie shot at it here. This looks like good news b/c the more 'indications' a new drug has, the broader it is, making it more palatable for big pharma (Glaxo, Pfizer, Merck etc.) to buy it.
From what I read last night, most of the FDA decision will be based on a trial published earlier this year called the MARINE trial which showed that this drug could significantly lower triglycerides on its own without much change to the LDL (bad cholesterol) levels... however that study probably wasn't powered enough to detect changes to the LDL-C.
This new trial ANCHOR (I actually thought this was available for people to read already?), basically says that the drug is o.k. to use with another drug to lower the LDL-C levels.
The REDUCE-IT trial is a study that is just starting up at the moment that tells us whether or not this drug will have any real meaning in the future. Sure it can lower triglycerides, and might help lower LDL levels too... but does it actually prevent heart attacks, strokes etc.
Quote:
The favorable ANCHOR trial results provide a strong rationale for conducting Amarin's REDUCE-IT trial, the cardiovascular outcomes study of AMR101, which is currently recruiting patients at high risk for cardiovascular events."
My interpretation is that things are looking good. Should probably wait for strykn to chime in though.
My AFC gave me an ABS CEL code of LOL while at WOT!
Join Date: Mar 2004
Location: LANGFORD!
Posts: 1,883
Thanked 1 Time in 1 Post
Anyone get in on six flags this morning? It looked to be $70+ before the markets opened. Is there a good way to view the markets before they open and after they close?
You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, join our community today!
The banners on the left side and below do not show for registered users!
You need G's bro unless your some fucking option wizard but options commission is $$$$ so.. you figure it out.
